Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review

In 1952, renal cell carcinomas had been divided into 2 categories-clear cell or granular cell- depending upon their cytoplasmic staining characteristics. In the following years, the inventory of renal epithelial tumors has expanded by the addition of tumors named by their architectural pattern (i.e., papillary RCC, tubulocystic RCC), anatomic location (i.e., collecting duct carcinoma, renal medullary carcinoma), associated diseases (i.e., acquired cystic disease-associated RCCs). With the extensive application of molecular diagnostic techniques, it becomes possible to detect genetic distinctions between various types of renal neoplasm and discover new entities, otherwise misdiagnosed or diagnosed as unclassified RCC. Some tumors such as ALK rearrangement-associated RCC, MiT family translocation renal carcinomas, SDH-deficient renal cancer or FH-deficient RCC, are defined by their molecular characteristics. The most recent World Health Organization (WHO) classification of renal neoplasms account for more than 50 entities and provisional entities. New entities might be included in the upcoming WHO classification. The aim of this review is to summarise and discuss the newly acquired data and evidence on the clinical, pathological, molecular features and on the prognosis of new RCC entities, which will hopefully increase the awareness and the acceptance of these entities among clinicians and improve prognostication for individual patients.

Automated summary

With the application of molecular diagnostic techniques, renal cell carcinomas have been categorized into various types, with the most recent WHO classification including over 50 entities. The aim of this review is to summarize new data and evidence on the clinical, pathological, molecular features, and prognosis of new RCC entities in order to increase awareness among clinicians and improve prognostication for individual patients.